Publication
PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data
| dc.contributor.author | Aguiar, Pedro N., Jr. | |
| dc.contributor.author | De Mello, Ramon Andrade | |
| dc.contributor.author | Hall, Peter | |
| dc.contributor.author | Tadokoro, Hakaru | |
| dc.contributor.author | de Lima, Gilberto | |
| dc.date.accessioned | 2019-11-20T15:07:37Z | |
| dc.date.available | 2019-11-20T15:07:37Z | |
| dc.date.issued | 2017-05 | |
| dc.description.abstract | Aim: The treatment of non-small-cell lung cancer has changed after the development of the immune checkpoint inhibitors. Although the most studied biomarker is the tumor programmed death ligand one (PD-L1) expression, its clinical significance is still debatable. In this article, we show the updated survival analysis of all published data. Methods: We searched in network and conference data sources for relevant clinical studies of immunotherapy for non-small-cell lung cancer that assessed the PD-L1 expression even as an exploratory analysis. The updated survival hazard ratios (HR) were included in the analysis. Results: 14 studies with 2857 patients were included (2019 treated with immunotherapy). The response rate was as higher among PD-L1-positive patients (RR: 2.19, 95% CI: 1.63-2.94). PD-L1 expression was also related to better progression-free survival (HR: 0.69, 95% CI: 0.57-0.85) and better overall survival (HR: 0.77, 95% CI: 0.67-0.89). Conclusion: PD-L1 overexpression predicts activity as well as better survival for patients treated with immune checkpoint inhibitors. | |
| dc.description.sponsorship | Pierre Fabre | |
| dc.description.sponsorship | Amgem | |
| dc.description.version | info:eu-repo/semantics/publishedVersion | |
| dc.identifier.doi | 10.2217/imt-2016-0150 | |
| dc.identifier.issn | 1750-743X | |
| dc.identifier.issn | 1750-7448 | |
| dc.identifier.uri | http://hdl.handle.net/10400.1/13131 | |
| dc.language.iso | eng | |
| dc.peerreviewed | yes | |
| dc.publisher | Future Medicine | |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
| dc.subject | Solid tumors | |
| dc.subject | Nivolumab | |
| dc.subject | Metaanalysis | |
| dc.subject | Guidelines | |
| dc.subject | Safety | |
| dc.subject | Docetaxel | |
| dc.subject | Therapy | |
| dc.subject | Nsclc | |
| dc.title | PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data | |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.citation.endPage | 506 | |
| oaire.citation.issue | 6 | |
| oaire.citation.startPage | 499 | |
| oaire.citation.title | Immunotherapy | |
| oaire.citation.volume | 9 | |
| person.familyName | de Mello | |
| person.givenName | Ramon Andrade | |
| person.identifier.orcid | 0000-0002-9640-4573 | |
| rcaap.rights | restrictedAccess | |
| rcaap.type | article | |
| relation.isAuthorOfPublication | 53ee625f-c5c3-468b-85bb-4cef5ad36928 | |
| relation.isAuthorOfPublication.latestForDiscovery | 53ee625f-c5c3-468b-85bb-4cef5ad36928 |
Files
Original bundle
1 - 1 of 1